Lupin Ltd. (LPC), India’s third-largest drugmaker by market value, expects to gain share in the U.S. amid increased regulatory oversight and curbs on competitors including Ranbaxy Laboratories Ltd. (RBXY)
Lupin’s track record on quality and the overlap of drug portfolios with Ranbaxy and Wockhardt Ltd. (WPL) gives it an opportunity to add sales in its largest market, Chief Executive Officer Vinita Gupta said in a telephone interview.
“With the recent issues with Ranbaxy API, we’re still waiting to see what happens,” Gupta said Feb. 3 of the Food and Drug Administration’s ban on Ranbaxy’s Toansa plant, which makes a bulk of its drug ingredients for the U.S. “Whenever these events happen, we keep very close to the ground to look at any opportunities we may have to pick up additional share.”
Lupin, founded by Gupta’s billionaire father Desh Bandhu Gupta, will look to tap demand for products such as cardiovascular medicines and heartburn treatment esomeprazole, or generic Nexium, that Ranbaxy makes, Gupta said. The Mumbai-based company could be one of the generic drugmakers that benefit if Ranbaxy isn’t able to secure an alternate source of ingredients or sell rights to its copy of AstraZeneca Plc’s Nexium, which had U.S. sales of $2 billion, according to Barclays Bank Plc analyst Balaji Prasad. Read more..
Lupin’s track record on quality and the overlap of drug portfolios with Ranbaxy and Wockhardt Ltd. (WPL) gives it an opportunity to add sales in its largest market, Chief Executive Officer Vinita Gupta said in a telephone interview.
“With the recent issues with Ranbaxy API, we’re still waiting to see what happens,” Gupta said Feb. 3 of the Food and Drug Administration’s ban on Ranbaxy’s Toansa plant, which makes a bulk of its drug ingredients for the U.S. “Whenever these events happen, we keep very close to the ground to look at any opportunities we may have to pick up additional share.”
Lupin, founded by Gupta’s billionaire father Desh Bandhu Gupta, will look to tap demand for products such as cardiovascular medicines and heartburn treatment esomeprazole, or generic Nexium, that Ranbaxy makes, Gupta said. The Mumbai-based company could be one of the generic drugmakers that benefit if Ranbaxy isn’t able to secure an alternate source of ingredients or sell rights to its copy of AstraZeneca Plc’s Nexium, which had U.S. sales of $2 billion, according to Barclays Bank Plc analyst Balaji Prasad. Read more..
Source: Hindi News
No comments:
Post a Comment